Evidence map›Paper›PMID 33141875›Full record

ArticlePloS one2020

A Tenon's capsule/bulbar conjunctiva interface biomimetic to model fibrosis and local drug delivery.

Katarzyna Kozdon, Bruna Caridi, Iheukwumere Duru, Daniel G Ezra, James B Phillips, Maryse Bailly

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Histology and histopathology · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Immune responses to injury and their links to eye disease.Translational research : the journal of laboratory and clinical medicine · 2021
    Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Katarzyna KozdonUCL Institute of Ophthalmology, UCL, London, United Kingdom.ORCID 0000-0002-8006-8982
Bruna CaridiUCL Institute of Ophthalmology, UCL, London, United Kingdom.
Iheukwumere DuruUCL Institute of Ophthalmology, UCL, London, United Kingdom.ORCID 0000-0002-8880-4278
Daniel G EzraUCL Institute of Ophthalmology, UCL, London, United Kingdom.
James B PhillipsDepartment of Pharmacology, UCL School of Pharmacy, UCL, London, United Kingdom.
Maryse BaillyUCL Institute of Ophthalmology, UCL, London, United Kingdom.ORCID 0000-0002-0593-6356
University College London · GBMoorfields Eye Hospital · GB

Funding

Department of Health
6 · The paper itself

Abstract

Glaucoma filtration surgery is one of the most effective methods for lowering intraocular pressure in glaucoma. The surgery efficiently reduces intra-ocular pressure but the most common cause of failure is scarring at the incision site. This occurs in the conjunctiva/Tenon's capsule layer overlying the scleral coat of the eye. Currently used antimetabolite treatments to prevent post-surgical scarring are non-selective and are associated with potentially blinding side effects. Developing new treatments to target scarring requires both a better understanding of wound healing and scarring in the conjunctiva, and new means of delivering anti-scarring drugs locally and sustainably. By combining plastic compression of collagen gels with a soft collagen-based layer, we have developed a physiologically relevant model of the sub-epithelial bulbar conjunctiva/Tenon's capsule interface, which allows a more holistic approach to the understanding of subconjunctival tissue behaviour and local drug delivery. The biomimetic tissue hosts both primary human conjunctival fibroblasts and an immune component in the form of macrophages, morphologically and structurally mimicking the mechanical proprieties and contraction kinetics of ex vivo porcine conjunctiva. We show that our model is suitable for the screening of drugs targeting scarring and/or inflammation, and amenable to the study of local drug delivery devices that can be inserted in between the two layers of the biomimetic. We propose that this multicellular-bilayer engineered tissue will be useful to study complex biological aspects of scarring and fibrosis, including the role of inflammation, with potentially significant implications for the management of scarring following glaucoma filtration surgery and other anterior ocular segment scarring conditions. Crucially, it uniquely allows the evaluation of new means of local drug delivery within a physiologically relevant tissue mimetic, mimicking intraoperative drug delivery in vivo.

Indexed as

Biomimetic MaterialsAnimalsBiomimeticsCell LineCicatrixConjunctivaDrug Delivery SystemsDrug Evaluation, PreclinicalFeasibility StudiesFibroblastsFibrosisFiltering SurgeryGlaucomaHumansIntraoperative CareMonocytes

Identifiers

PMID33141875
PMCPMC7608904
OpenAlexW3096711841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.